Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After...
Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After...
愛德華生命科學表示,EARLY TAVR試驗顯示,在最初的6個月內,臨床監測組中有26.2%的患者轉爲AVR,許多患者出現進行性或先進症狀;在隨機分組後的12個月後隨訪期間...
Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After Randomization, The Rate Of Conversion To AVR Was 47.2%
愛德華生命科學表示,EARLY TAVR試驗顯示,在最初的6個月內,臨床監測組中有26.2%的患者轉爲AVR,許多患者出現進行性或先進症狀;在隨機分組後的12個月隨訪期後,轉爲AVR的比例爲47.2%
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。